Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
David Cunningham(Royal Marsden NHS Foundation Trust), Daniel Virgil Thomas Catenacci(University of Chicago), Sergei Tjulandin, Igor Bondarenko(Dnipro State Medical University), Anghel Adrian Udrea, Nigel Baker(Amgen (United Kingdom)), David H. Ilson(Memorial Sloan Kettering Cancer Center), Evgeny Gotovkin(Ivanovo State Medical Academy), Kelly S. Oliner(Amgen (United States)), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Niall C. Tebbutt(Austin Health), Bogusława Karaszewska(State University of Applied Sciences in Konin), Yilong Zhang(Otsuka (Japan)), André M. Murad(Hospital das Clínicas da Universidade Federal de Minas Gerais), Roger Sidhu(Amgen (United States)), Tien Hoang(Amgen (United States)), Ірина Давиденко(Specialized Clinical Psychiatric Hospital No. 1), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando)
Cited by 144
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k